Rivanna Joins Medtech Innovator 2025 Cohort with Groundbreaking Ultrasound Tech

Rivanna’s Selection for the Medtech Innovator 2025 Accelerator Cohort

Image Credits: Rivanna Medical

Announcement

Rivanna, a leading manufacturer and medical device innovator known for its imaging-based medical solutions, proudly announced its ticket to join the Medtech Innovator 2025 accelerator cohort. Rivanna becomes the first ever company to be selected for this program to representing 4% of 1,500 global participants amongst 65 companies. The selection of Rivanna was possible due to its innovation of Accuro 3S.

Innovation

The Accuro 3S is the first AI-enabled technology for an ultrasound guidance system introduced to expand its ultrasound-guided regional anesthesia benefits to procedures like spinal blocks and epidurals. The Accuro 3S identifies clinical challenges by providing image-guided needle placement in real-time, where a conventional ultrasound system slows down. The development of this solution is interconnected with the MTI’s mission of enabling enhancement in patient care through effective technology.

Program

MedTech Innovator (MTI) is a boon for medical technology startups. The four-month program enables participants to get access to strategic guidance and gain valuable insights from professional mentors. It also introduces new connections like payers, providers, industry experts, investors, and manufacturers.

Currently, during the program, cohort companies will mark their attendance at major industry events like the Medtech conference powered by AdvaMed in San Diego from 5-8 October and the Medtech Strategist Innovation Summit in San Diego from 19-21. Here, the cohort companies will compete for a $800000 share under non-dilutive funding.

How do Government Programs Encourage Innovation in the Healthcare Market?

Various governmental schemes and programs bolster the healthcare management and encourage innovations in the development process. The establishment of new partnerships and promoting innovation, attracting investors through government contributions, enhances capital, and builds a strong healthcare infrastructure. The MTI program will benefit Rivanna by expanding and introducing innovation to the healthcare platform. Technology in science and other fields of medicine is an advancement to both innovator and investor. The government’s initiative to provide a huge platform is a valuable investment and contribution to the Rivanna. This will strengthen the internal engagement of the program initiators.

Views and Statements

PhD, Cofounder and CEO of Rivanna, Will Mauldin, said, “The selection in this year’s medtech innovator cohort is a meaningful and valuable promotion of the company’s commitment to advance and improve procedural safety.” He further added, “The company’s technology platform is leading in identifying longstanding challenges to neuraxial anesthesia. This will open doors for an opportunity to strengthen industrial partnership, validate technology, and elevate commercialization of the company.”